AT540954T - Aminoheterocyclische verbindungen - Google Patents

Aminoheterocyclische verbindungen

Info

Publication number
AT540954T
AT540954T AT08737600T AT08737600T AT540954T AT 540954 T AT540954 T AT 540954T AT 08737600 T AT08737600 T AT 08737600T AT 08737600 T AT08737600 T AT 08737600T AT 540954 T AT540954 T AT 540954T
Authority
AT
Austria
Prior art keywords
etherocyclic
amino
compounds
Prior art date
Application number
AT08737600T
Other languages
English (en)
Inventor
Patrick Verhoest
Caroline Proulx-Lafrance
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US91733307P priority Critical
Application filed by Pfizer filed Critical Pfizer
Priority to PCT/IB2008/001125 priority patent/WO2008139293A1/en
Publication of AT540954T publication Critical patent/AT540954T/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT08737600T 2007-05-11 2008-05-05 Aminoheterocyclische verbindungen AT540954T (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US91733307P true 2007-05-11 2007-05-11
PCT/IB2008/001125 WO2008139293A1 (en) 2007-05-11 2008-05-05 Amino-heterocyclic compounds

Publications (1)

Publication Number Publication Date
AT540954T true AT540954T (de) 2012-01-15

Family

ID=39672073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08737600T AT540954T (de) 2007-05-11 2008-05-05 Aminoheterocyclische verbindungen

Country Status (44)

Country Link
US (1) US7964607B2 (de)
EP (1) EP2152712B1 (de)
JP (1) JP4579346B2 (de)
KR (1) KR101222330B1 (de)
CN (1) CN101687876B (de)
AP (1) AP2524A (de)
AR (1) AR066502A1 (de)
AT (1) AT540954T (de)
AU (1) AU2008249750B2 (de)
BR (1) BRPI0811280A2 (de)
CA (1) CA2687035C (de)
CL (1) CL2008001374A1 (de)
CO (1) CO6241157A2 (de)
CR (1) CR11095A (de)
CU (1) CU23834B1 (de)
CY (1) CY1112332T1 (de)
DK (1) DK2152712T3 (de)
DO (1) DOP2009000258A (de)
EA (1) EA016510B1 (de)
EC (1) ECSP099728A (de)
ES (1) ES2377849T3 (de)
GE (1) GEP20125405B (de)
GT (1) GT200900294A (de)
HK (1) HK1142595A1 (de)
HR (1) HRP20120105T1 (de)
IL (1) IL201977A (de)
MA (1) MA31373B1 (de)
ME (1) ME00954B (de)
MX (1) MX2009011830A (de)
MY (1) MY147330A (de)
NI (1) NI200900204A (de)
NZ (1) NZ580904A (de)
PA (1) PA8779901A1 (de)
PE (1) PE20090247A1 (de)
PL (1) PL2152712T3 (de)
PT (1) PT2152712E (de)
RS (1) RS52166B (de)
SI (1) SI2152712T1 (de)
SV (1) SV2009003411A (de)
TN (1) TN2009000471A1 (de)
TW (1) TWI362262B (de)
UA (1) UA94660C2 (de)
WO (1) WO2008139293A1 (de)
ZA (1) ZA200907776B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selective phosphodiesterase 9A inhibitors as drugs to improve cognitive processes
CA2706018C (en) 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
CA2716410C (en) 2008-04-02 2017-03-28 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
CN102365285B (zh) 2009-03-31 2014-08-06 贝林格尔.英格海姆国际有限公司 1-杂环基-1，5-二氢-吡唑并[3，4-d]嘧啶-4-酮衍生物及其作为pde9a调节剂的用途
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
ES2396300T3 (es) 2008-11-19 2013-02-20 Envivo Pharmaceuticals, Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2429518A1 (de) * 2009-05-11 2012-03-21 Envivo Pharmaceuticals, Inc. Behandlung von kognitiven erkrankungen mit bestimmten alpha-7-nikotinsäure-rezeptoren in kombination mit acetylcholinesterase-inhibitoren
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Organic compounds
EP2485771A4 (de) * 2009-10-08 2014-11-12 Intra Cellular Therapies Inc Auf phosphodiesterase 1 abgezielte tracer und verfahren
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
EP2619208B1 (de) * 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Imidazotriazinonverbindungen
US8809345B2 (en) * 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
SG11201400717QA (en) 2011-10-07 2014-06-27 Eisai R&D Man Co Ltd Pyrazoloquinoline derivative
BR112015007731A2 (pt) 2011-10-10 2017-07-04 H Lundbeck As pde9i com cadeia principal de imidazo pirazinona
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
EP2828262A4 (de) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc Imidazotriazinonverbindungen
EP3461481A1 (de) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Verfahren zur aufrechterhaltung, behandlung oder verbesserung der kognitiven funktion
ES2637245T3 (es) 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CN105121440B (zh) 2013-04-05 2017-05-24 卫材R&D管理有限公司 吡唑并喹啉衍生物的盐及其晶体
MX363258B (es) 2013-04-05 2019-03-19 Eisai R&D Man Co Ltd PIRIDINYLPIRAZOLOQUINOLINE COMPOUNDS.
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
BR112017005533A2 (pt) * 2014-09-17 2017-12-05 Intra Cellular Therapies Inc compounds and methods
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 Triazolopyridinone as a PDE1 inhibitor
CA2969594A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
KR20170089001A (ko) * 2014-12-06 2017-08-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
TWI695838B (zh) 2015-04-30 2020-06-11 丹麥商Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並吡酮
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
SG10201913989QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
TW201738242A (zh) 2016-04-12 2017-11-01 Ｈ 朗德貝克公司 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridine as PDE1 inhibitor -4-ketone
CN109475556A (zh) 2016-07-06 2019-03-15 伊马拉公司 用于治疗外周疾病的pde9抑制剂
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
KR20200016891A (ko) * 2017-05-26 2020-02-17 이마라 인크. Methods of Making and Using PDE9 Inhibitors
WO2020086481A1 (en) * 2018-10-21 2020-04-30 Intra-Cellular Therapies, Inc. Novel uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
EP1396488A1 (de) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Kondensierte heterocyclische verbindung und deren medizinische verwendung
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2004008230A2 (en) * 2002-07-12 2004-01-22 Massachusetts Institute Of Technology Reconfigurable microphotonics devices via deformable membrane platform
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selective phosphodiesterase 9A inhibitors as drugs to improve cognitive processes
US7051174B2 (en) * 2002-09-24 2006-05-23 International Business Machines Corporation Method, system, and program for restoring data in cache
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
US7111287B2 (en) * 2003-01-10 2006-09-19 International Business Machines Corporation Global processor resource assignment in an assembler
AT368666T (de) 2003-03-18 2007-08-15 Jordanian Pharmaceutical Mfg Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-arylmethyl substituted pyrazolopyrimidines

Also Published As

Publication number Publication date
MA31373B1 (fr) 2010-05-03
EA200901373A1 (ru) 2010-06-30
SI2152712T1 (sl) 2012-03-30
RS52166B (en) 2012-08-31
AP200905048A0 (en) 2009-12-31
GT200900294A (es) 2011-08-29
IL201977A (en) 2014-07-31
NZ580904A (en) 2012-02-24
KR101222330B1 (ko) 2013-01-15
TN2009000471A1 (fr) 2011-03-31
NI200900204A (es) 2010-03-11
CL2008001374A1 (es) 2008-11-14
IL201977D0 (en) 2010-06-16
AU2008249750B2 (en) 2011-07-14
WO2008139293A1 (en) 2008-11-20
SV2009003411A (es) 2010-05-21
EA016510B1 (ru) 2012-05-30
JP4579346B2 (ja) 2010-11-10
TW200902015A (en) 2009-01-16
AP2524A (en) 2012-12-04
ME00954B (me) 2012-06-20
PE20090247A1 (es) 2009-03-13
BRPI0811280A2 (pt) 2015-01-20
ZA200907776B (en) 2011-01-26
CU23834B1 (es) 2012-10-15
UA94660C2 (en) 2011-05-25
US7964607B2 (en) 2011-06-21
DOP2009000258A (es) 2010-05-15
MY147330A (en) 2012-11-30
GEP20125405B (en) 2012-02-27
CR11095A (es) 2009-12-04
HK1142595A1 (en) 2010-12-10
EP2152712A1 (de) 2010-02-17
CU20090184A7 (es) 2011-07-11
ECSP099728A (es) 2009-12-28
EP2152712B1 (de) 2012-01-11
HRP20120105T1 (xx) 2012-02-29
CY1112332T1 (xx) 2015-12-09
ES2377849T3 (es) 2012-04-02
CN101687876A (zh) 2010-03-31
CN101687876B (zh) 2012-12-12
CO6241157A2 (es) 2011-01-20
TWI362262B (en) 2012-04-21
CA2687035C (en) 2011-09-20
PA8779901A1 (es) 2008-12-18
MX2009011830A (es) 2009-11-13
US20090030003A1 (en) 2009-01-29
AR066502A1 (es) 2009-08-26
KR20100007985A (ko) 2010-01-22
PT2152712E (pt) 2012-02-29
CA2687035A1 (en) 2008-11-20
DK2152712T3 (da) 2012-03-26
PL2152712T3 (pl) 2012-05-31
JP2010526863A (ja) 2010-08-05
AU2008249750A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
DK2209856T3 (da) Aerogelsammensætninger
DK2665193T3 (da) Styrekanalallokering
DK2205737T3 (da) Mikromirer
DK2158214T3 (da) Glukagonanaloger
DK2522667T3 (da) Morphinanforbindelser
DK2170321T3 (da) Ormekur-kombination
DK2121534T3 (da) Enkeltrudelaminater
DK2124668T3 (da) Hårplejeindretning
DK2242759T3 (da) Forbindelser
DK2195058T3 (da) Laryngealmaske
DK2514818T3 (da) Glucoamylasevarianter
AT525702T (de) Erweiterte widgetarchitektur
DK2203551T3 (da) Bifidobakterieart
AT531723T (de) Steviolglycosidisomere
BRPI0817238A2 (pt) Transconector
AT511375T (de) Getränkeaufbrüheinheit
AT513978T (de) Drehsteuervorrichtungsandockstation
AT512633T (de) Wirbelsäulen-verbindungselement
AT544742T (de) Insektizide arylpyrrolidine
BRPI0814563A2 (pt) Nanosuperfície
AT530279T (de) Tangentialschneideeinsatz
DK2159224T3 (da) Bromphenylsubstituerede thiazolyldihydropyrimidiner
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
DE602008002066D1 (de) Iorekonstruktion